Ovarian Cancer-Pipeline Insights, 2016

Description: “Ovarian Cancer -Pipeline Insights, 2016” provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under the category of Ovarian Cancer. Ovarian cancer is the sudden growth of the cells in the ovary and is a type of cancer that affects females only. The cancer forms in tissues of the ovary when normal cells are affected. It can affect either one or both the ovaries.

It is estimated that every year approximately 21,000 women in USA and 5,500 women in UK are diagnosed with ovarian cancer. It is the eighth most common cancer among women in USA and fifth most common cancer among females in UK. The report provides the in-depth analysis of the pipeline assets across the Ovarian Cancer. The Report gives insights on 225+ products. It also includes around 185+ companies which are active in this field. Ovarian Cancer -Pipeline Insights, 2016 Report covers the pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases.

The Report also provides Ovarian Cancer related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for Ovarian Cancer. These days’ companies are focusing on the Targeted Therapy for cancer. Roche’s Pertuzumab, Merck Avelumab and Morphotek’s Farletuzumab is the monoclonal antibody in Phase III stage competing against the other small molecules in development. Many big pharmaceuticals companies are involved in ovarian cancer with their preregistration products. Cediranib of AstraZeneca and Paclitaxel of Oasmia Pharmaceutical AB is ready to hit the market in few coming years. These are in preregistration stage of development.

Note: This report will be delivered to the client in 48 hours

Report Highlights:
- The new report, provides a Ovarian Cancer Landscape across the globe
- The report provides drug profiles which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, Preclinical and Discovery stages
- Coverage of the Ovarian Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Ovarian Cancer and also provide company profiling
- Pipeline products coverage based on various stages of development from NDA filings to discovery.
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type.

Contents:
- Table of Contents
  - Ovarian Cancer Overview
  - Signs and symptoms
  - Diagnosis
  - Treatment
  - Pipeline Therapeutics
  - Therapeutics under Development by Companies
  - Last Stage Products (Phase III)
  - Comparative Analysis
  - Mid Stage Products (Phase II)
  - Comparative Analysis
  - Early Stage Products (Phase I and IND)
  - Comparative Analysis
  - Discovery and Pre-clinical stage Products
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dormant Products
- Comparative Analysis
- Discontinued Products
- Comparative Analysis
- Appendix
- Methodology
- Consulting Services
- About us
- Contact Us
- Disclaimer

List of Tables
- 1: Number of Products Under Development for Ovarian cancer, 2016
- Table 2: Number of Products under Development by Companies, 2016
- Table 3: Last Stage Products (Phase III and Filed), 2016
- Table 4: Mid Stage Products (Phase II), 2016
- Table 5: Early Stage Products (Phase I), 2016
- Table 6: Pre-Clinical and Discovery Products, 2016
- Table 7: Assessment by Monotherapy Products, 2016
- Table 8: Assessment by Combination Products, 2016
- Table 9: Assessment by Route Of Administration, 2016
- Table 10: Assessment by Stage and Route Of Administration, 2016
- Table 11: Assessment by Molecule Type, 2016
- Table 12: Assessment by Stage and Molecule Type, 2016
- Table 13: Dormant Products, 2016
- Table 14: Discontinued Products, 2016

List of Figures
- Figure 1: Number of Products under Development for Ovarian cancer, 2016
- Figure 2: Last Stage Products (Phase III), 2016
- Figure 3: Mid Stage Products (Phase II), 2016
- Figure 4: Early Stage Products (Phase I), 2016
- Figure 5: Discovery and Pre-clinical Stage Products, 2016
- Figure 6: Assessment by Monotherapy Products, 2016
- Figure 7: Assessment by Combination Products, 2016
- Figure 8: Assessment by Route of Administration, 2016
- Figure 9: Assessment by Stage and Route of Administration, 2016
- Figure 10: Assessment by Molecule Type, 2016
- Figure 11: Assessment by Stage and Molecule Type, 2016
- Figure 12: Dormant Products, 2016
- Figure 13: Discontinued Products, 2016

Ordering:
Order Online - [http://www.researchandmarkets.com/reports/3774308/](http://www.researchandmarkets.com/reports/3774308/)
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Ovarian Cancer-Pipeline Insights, 2016
Web Address: http://www.researchandmarkets.com/reports/3774308/
Office Code: SCPLTN4S

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2250</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4500</td>
</tr>
<tr>
<td>Electronic (PDF) - Ent. License</td>
<td></td>
<td>USD 6750</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof  [ ]
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World